Product: | Dasatinib | ||||
---|---|---|---|---|---|
Catalog Number: | 8751 | ||||
CAS Number: | 302962-49-8 | ||||
Synonyms: |
N-[2-Chloro-6-methylphenyl]-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide; BMS-354825; Sprycel; N-(2-CHLORO-6-METHYLPHENYL)-2-([6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL]AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE |
||||
Pricing: |
|
||||
Formula: | C22H26ClN7O2S | ||||
Chemical Purity: | 99% | ||||
Molecular Weight: | 488.01 | ||||
Structure: | |||||
Appearance: | White or off-white powder/crystalline solid. | ||||
Category: | Anti-cancer compounds | ||||
Literature References: |
Das J et al., 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J Med Chem, 2006, 49 (23): 6819–32.; Talpaz M, Shah NP, Kantarjian H et al., Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med., 2006, 354 (24): 2531–41. |
||||
MSDS: | |||||
Applications: | A Bcr-Abl tyrosine kinase inhibitor. Used as a first line cancer drug to treat chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. |